Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Zoledronic acid (Primary) ; Calcium; Colecalciferol; Letrozole
- Indications Metabolic bone diseases; Osteoporosis
- Focus Therapeutic Use
- 11 Sep 2019 Biomarkers information updated
- 13 Nov 2012 Planned end date changed from 1 Jun 2008 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 16 Mar 2011 Planned end date (Jun 2008) added as reported by ClinicalTrials.gov.